Background: As the pandemic of Coronavirus disease (COVID-19) progresses, health care remains a new challenge. The recent rise in second wave possess a different challenge of opportunistic infections especially Mucormycosis in COVID-19 recovered patients. It is complicating their future outcomes and making quality of life more Morbid. Mucormycosis was well known to infect patients with immunocompromised conditions, as the treatment of COVID-19 largely rests on systemic steroids and other immunosuppressant’s the risk of invasive fungal infection has increased